Molecular Therapy: Oncolytics (Jun 2020)

miR-155 Accelerates the Growth of Human Liver Cancer Cells by Activating CDK2 via Targeting H3F3A

  • Xiaoru Xin,
  • Yanan Lu,
  • Sijie Xie,
  • Yingjie Chen,
  • Xiaoxue Jiang,
  • Shuting Song,
  • Liyan Wang,
  • Hu Pu,
  • Xin Gui,
  • Tianming Li,
  • Jie Xu,
  • Jiao Li,
  • Song Jia,
  • Dongdong Lu

Journal volume & issue
Vol. 17
pp. 471 – 483

Abstract

Read online

miR-155 is associated with the promotion of tumorigenesis. Herein, we indicate that abnormal miR-155 was negatively correlated with the expression of P21WAF1/Cip1. Our results suggest that miR-155 alters the transcriptome and inhibits the expression of H3F3A in liver cancer cells. Therefore, miR-155 inhibits the methylation modification of histone H3 on the 27th lysine. Notably, on the one hand, miR-155-dependent CTCF loops cause the CDK2 interacting with cyclin E in liver cancer cells; on the other hand, miR-155 promotes the phosphorylation modification of CDK2 by inhibiting H3F3A. Subsequently, miR-155 competitively blocks the binding of RNA polymerase II (RNA Pol II) to the P21WAF1/CIP1 promoter by increasing the phosphorylation of CDK2, inhibiting the transcription and translation of P21WAF1/CIP1. Strikingly, excessive P21WAF1/CIP1 abolishes the cancerous function of miR-155. In conclusion, miR-155 can play a positive role in the development of liver cancer and influence a series of gene expression through epigenetic regulation.

Keywords